Abstract | BACKGROUND: METHODS: EUROPA was a multicenter, double-blind, placebo-controlled, randomized trial in patients with documented stable CAD. Randomized EUROPA patients who received β-blocker at baseline were identified, and the effect on cardiovascular outcomes of adding perindopril or placebo was analyzed. Endpoints were the same as those in EUROPA. RESULTS: At baseline, 62% (n = 7534 [3789 on perindopril and 3745 on placebo]) received β-blocker. Treatment with perindopril/β-blocker reduced the relative risk of the primary end point (cardiovascular death, nonfatal myocardial infarction, and resuscitated cardiac arrest) by 24% compared with placebo/β-blocker (HR, 0.76; 95% CI, 0.64-0.91; P = .002). Addition of perindopril also reduced fatal or nonfatal myocardial infarction by 28% (HR, 0.72; 95% CI, 0.59-0.88; P = .001) and hospitalization for heart failure by 45% (HR, 0.55; 95% CI, 0.33-0.93; P = .025). Serious adverse drug reactions were rare in both groups, and cardiovascular death and hospitalizations occurred less often with perindopril/β-blocker. CONCLUSIONS: The addition of perindopril to β-blocker in stable CAD patients was safe and resulted in reductions in cardiovascular outcomes and mortality compared with standard therapy including β-blocker.
|
Authors | Michel E Bertrand, Roberto Ferrari, Willem J Remme, Maarten L Simoons, Kim M Fox |
Journal | American heart journal
(Am Heart J)
Vol. 170
Issue 6
Pg. 1092-8
(Dec 2015)
ISSN: 1097-6744 [Electronic] United States |
PMID | 26678630
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Perindopril
|
Topics |
- Adrenergic beta-Antagonists
(administration & dosage, adverse effects)
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(administration & dosage, adverse effects)
- Coronary Artery Disease
(diagnosis, drug therapy, mortality)
- Double-Blind Method
- Europe
(epidemiology)
- Female
- Hospitalization
(statistics & numerical data)
- Humans
- Male
- Middle Aged
- Outcome and Process Assessment, Health Care
- Patient Acuity
- Perindopril
(administration & dosage, adverse effects)
- Survival Analysis
- Treatment Outcome
|